NVO: Novo Nordisk A/S
NVO exchange rate has changed by -1.03% for today. During the day, the instrument was traded at a low of 40.43 and at a high of 41.29.
Follow Novo Nordisk A/S dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M30
- H1
- H4
- D1
- W1
- MN
NVO News
- Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
- Novo Nordisk: Why I Still Find It An Interesting Opportunity (NYSE:NVO)
- Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing? - TipRanks.com
- BME: Removal Of Option Writing Can Improve NAV Growth (NYSE:BME)
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 29 - TipRanks.com
- AbbVie: Strong 2026 Outlook, Expect Dividend Increases (NYSE:ABBV)
- Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
- WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
- VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
- Hims & Hers: The Reset Before The Next Inflection (NYSE:HIMS)
- Hims & Hers shifts business model after Novo deal
- ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
- Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
- ALT Pemvidutide Explained: What Makes It Different in MASH
- Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
- NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
- LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
- Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity (NYSE:NVO)
- LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
- FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
- NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
- LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
- Why Eli Lilly Remains My Top Obesity Bet (NYSE:LLY)
- Weight-loss drugs are changing the way people dress. These companies stand to benefit.
Frequently Asked Questions
What is NVO stock price today?
Novo Nordisk A/S stock is priced at 40.50 today. It trades within 40.43 - 41.29, yesterday's close was 40.92, and trading volume reached 19832. The live price chart of NVO shows these updates.
Does Novo Nordisk A/S stock pay dividends?
Novo Nordisk A/S is currently valued at 40.50. Dividend policy depends on the company, while investors also watch -41.14% and USD. View the chart live to track NVO movements.
How to buy NVO stock?
You can buy Novo Nordisk A/S shares at the current price of 40.50. Orders are usually placed near 40.50 or 40.80, while 19832 and -1.17% show market activity. Follow NVO updates on the live chart today.
How to invest into NVO stock?
Investing in Novo Nordisk A/S involves considering the yearly range 35.13 - 81.44 and current price 40.50. Many compare 10.14% and -18.03% before placing orders at 40.50 or 40.80. Explore the NVO price chart live with daily changes.
What are Novo Nordisk A/S stock highest prices?
The highest price of Novo Nordisk A/S in the past year was 81.44. Within 35.13 - 81.44, the stock fluctuated notably, and comparing with 40.92 helps spot resistance levels. Track Novo Nordisk A/S performance using the live chart.
What are Novo Nordisk A/S stock lowest prices?
The lowest price of Novo Nordisk A/S (NVO) over the year was 35.13. Comparing it with the current 40.50 and 35.13 - 81.44 shows potential long-term entry points. Watch NVO moves on the chart live for more details.
When did NVO stock split?
Novo Nordisk A/S has gone through stock splits historically. These changes are visible in , 40.92, and -41.14% after corporate actions.
- Previous Close
- 40.92
- Open
- 40.98
- Bid
- 40.50
- Ask
- 40.80
- Low
- 40.43
- High
- 41.29
- Volume
- 19.832 K
- Daily Change
- -1.03%
- Month Change
- 10.14%
- 6 Months Change
- -18.03%
- Year Change
- -41.14%